Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Feb 20;9(1):46.
doi: 10.1038/s41392-024-01770-y.

Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA

Lang Zheng  1 , Wenjing Wang  2   3 , Qiu Sun  4   5
Affiliations
Editorial

Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA

Lang Zheng et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
NMPA and FDA-approved targeted drugs by modality, 2023. a Small molecules and protein-based drugs comprised a significant majority of NMPA approvals, while oligonucleotides only represented a single case. b The majority of FDA approvals for targeted drugs consist of small molecules and protein-based drugs, with small molecules being approved as new molecular entities (NMEs). Approved in four cases, oligonucleotides were also classified as new molecular entities (NMEs). Source: NMPA, FDA and Nature Reviews Drug Discovery (10.1038/d41573-024-00001-x)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mullard, A. 2023 FDA approvals. Nat. Rev. Drug Discov.10.1038/d41573-024-00001-x (2024). - PubMed
    1. Blair HA. Efbemalenograstim alfa: first approval. Drugs. 2023;83:1125–1130. doi: 10.1007/s40265-023-01911-7. - DOI - PubMed
    1. Allison, S. J. Daprodustat for anaemia in CKD. Nat. Rev. Nephrol. 18, 3 (2022). - PubMed
    1. Kang C. Avacincaptad pegol: first approval. Drugs. 2023;83:1447–1453. doi: 10.1007/s40265-023-01948-8. - DOI - PubMed

Publication types

Substances